GlassScriptPhysician profile
Michael W Foote
NPI 1275678492
$8,947.41
in general payments reported to CMS, 2019-2025
32 companies · $2,342 in 2025
The $2,342 reported for 2025 was more than what 90% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,974 · 2020: $245 · 2021: $962 · 2022: $865 · 2023: $1,074 · 2024: $1,485 · 2025: $2,342.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,777 · Consulting Fee: $47.61 · Honoraria: $38.86 · Gift: $20.03 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,776.73 |
| Consulting Fee | $47.61 |
| Honoraria | $38.86 |
| Gift | $20.03 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,360.95 | 2019-2025 | Eysuvis, Rocklatan, Hydrus Microstent |
| Bausch & Lomb Americas INC. | $1,233.98 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $798.01 | 2019-2025 | |
| Allergan, INC. | $679.82 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $620.30 | 2024-2025 | Xdemvy |
| Abbvie INC. | $558.87 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $556.77 | 2019-2021 | |
| Rxsight INC | $398.44 | 2023-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Novartis Pharmaceuticals Corporation | $381.39 | 2019-2023 | |
| Oyster Point Pharma, INC. | $343.63 | 2022-2025 | Tyrvaya |
| Glaukos Corporation | $264.11 | 2024-2025 | Idosetr, Istent, Radius |
| Dompe US, INC. | $253.24 | 2021-2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $235.39 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $228.27 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $212.55 | 2024-2025 | Veracity Surgical |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $210.15 | 2019-2025 | |
| Eyevance Pharmaceuticals LLC | $92.90 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $70.46 | 2019 | |
| Genzyme Corporation | $66.37 | 2021-2023 | |
| Sight Sciences, INC. | $56.93 | 2022-2025 | Omni Surgical System |
| Harrow Eye, LLC | $54.88 | 2025 | Vevye |
| Janssen Pharmaceuticals, INC | $44.91 | 2021 | |
| Staar Surgical Company | $39.87 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $33.89 | 2019 | |
| Tearlab Corp | $30.89 | 2019 | |
| Shire North American Group INC | $24.42 | 2019 | |
| Thea Pharma INC. | $23.04 | 2024 | Iyuzeh |
| New World Medical,INC. | $20.47 | 2024 | Clearpath, Ahmed Glaucoma Valve, Streamline |
| Celgene Corporation | $15.77 | 2021 | |
| Travere Therapeutics, INC. | $15.52 | 2019 | |
| Maculogix, INC. | $10.93 | 2019 | |
| Abb Con-Cise Optical Group LLC | $10.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Foote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.